XOMA XOMA Corporation

23.22
+0.04  (+0%)
Previous Close 23.18
Open 23.1
Price To Book 7.9
Market Cap 203,349,498
Shares 8,757,515
Volume 30,734
Short Ratio
Av. Daily Volume 86,805
Stock charts supplied by TradingView

NewsSee all news

  1. XOMA Announces Closing of Rights Offering

    EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced the closing of its previously announced rights offering (the "Rights Offering").  At the

  2. Iscalimab (CFZ533) Update

    EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA

  3. XOMA Announces Commencement of Rights Offering

    EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced it has commenced the previously announced rights offering to raise gross proceeds of

  4. XOMA Announces Proposed Rights Offering

    Rights Offering will be available to all shareholders of record on November 29, 2019$22 million to be raised; fully backstopped EMERYVILLE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA)

  5. XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) today reported its third quarter 2019 financial results.  "XOMA's portfolio of future potential royalty- and milestone-generating

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 2 proof-of-concept results released April 24, 2017.
XOMA 213
Hyperprolactinemia
Phase 1 initiation of patient dosing announced June 13, 2019.
Gevokizumab
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma

Latest News

  1. XOMA Announces Closing of Rights Offering

    EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced the closing of its previously announced rights offering (the "Rights Offering").  At the

  2. Iscalimab (CFZ533) Update

    EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA

  3. XOMA Announces Commencement of Rights Offering

    EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced it has commenced the previously announced rights offering to raise gross proceeds of

  4. XOMA Announces Proposed Rights Offering

    Rights Offering will be available to all shareholders of record on November 29, 2019$22 million to be raised; fully backstopped EMERYVILLE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA)

  5. XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) today reported its third quarter 2019 financial results.  "XOMA's portfolio of future potential royalty- and milestone-generating

  6. XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million

  7. XOMA to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global

  8. XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company's business at the H.C. Wainwright